Skip to main
IMUX

Immunic Inc (IMUX) Stock Forecast & Price Target

Immunic Inc (IMUX) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Immunic is poised for success as their selective oral immunology therapies show promise in treating chronic inflammatory and autoimmune diseases. With a strong pipeline of small molecule products in development and potential indication expansions in multiple sclerosis, the company is well-positioned for growth. The recent positive Phase 2 trial results for vidofludimus calcium in relapsing-remitting multiple sclerosis bode well for the ongoing Phase 3 ENSURE program, with promising efficacy data on relapse and confirmed disability progression. Investors should closely monitor the topline results from the ENSURE trials, as well as the potential launch of a Phase 3 program for primary progressive multiple sclerosis later in 2026.

Bears say

Immunic is a clinical-stage biopharmaceutical company operating in one segment. However, their small molecule products are still in the early stages of development and have no guarantee of success, and the recent 1-for-10 reverse stock split and potential follow-on financing activity create additional technical and dilution risks. Meanwhile, current oral therapies for RMS only target inflammation and relapses, leaving a gap in addressing disability progression. These factors, along with potential market share risk, contribute to the negative outlook for the stock.

Immunic Inc (IMUX) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immunic Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immunic Inc (IMUX) Forecast

Analysts have given Immunic Inc (IMUX) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Immunic Inc (IMUX) has a Strong Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.92, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.92, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immunic Inc (IMUX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.